Urothelial carcionoma
Conditions
Interventions
The regimen is triweekly. Patients receive 200mg/m2 paclitaxel that is administered by intravenous (IV) infusion on Day 1 and 1,000mg/m2 gemcitabine that is administered by IV infusion on Day 1, 8 a
Sponsors
Saiseikai Yokohamashi Tobu Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. written informed consent 2. Urothelial cancer was (must be) confirmed by histological or cytological methods. 3. adjuvant or neoadjuvant setting, locally advanced (T4b, N1-3) or metastatic urothelial cancer who are not eligible for radical surgery 4. Patients had measurable diseases. 5. Regardless of the objectives, CDDP-resistant urothelial cancer or patients who cannot receive cisplatin due to renal dysfunction. 6. PS 0-2 7. Prior chemotherapy with taxan was not allowed.
Exclusion criteria
Exclusion criteria: 1. prior chemotherapy with paclitaxel 2. patients with interstitial pneumoniae and pulmonary fibrosis 3. patients with body fluid with the necessity of drainage or severe edema 4. patients with brain metastasis with the necessity of treatment 5. active double cancer 6. severe or uncontrollable complications 7. patients with allergy to polyoxyethylene castor oil-contain drug (e.g., CDDP) or sclerosing castor oil-contain drug (e.g., injectable vitamins) 8. Not eligible for patients during Pregnancy or Lactation, and with the hope of pregnancy 9. Prior therapy is allowed if this is completed more than 28 days before study entry. 10. Otherwise, patients are judged to be not eligible by the attending doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival, disease specific survival, side effect | — |
Secondary
| Measure | Time frame |
|---|---|
| tumor size, symptom | — |
Countries
Japan
Contacts
Public ContactMasaru Ishida
Saiseikai Yokohamashi Tobu Hospital Urology
Outcome results
None listed